Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
ranules now has a total of 38 ANDA approvals from US FDA.
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Lifts full-year outlook as obesity drug boom accelerates
But acquisition charges drag earnings into loss
Patalganga plant received zero observation from USFDA earlier
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Subscribe To Our Newsletter & Stay Updated
